Kalos Management’s Array Biopharma Inc ARRY Stock Holding History

Kalos Management’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-11,177	Closed	-$143K	–	227
2017 Q4	$143K	Buy	+11,177	New	+$127K	0.07%	200

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Kalos Management's ARRY Position: Q1 2018 in Review

Kalos Management sold out of Array Biopharma Inc (ARRY) in Q1 2018, closing a stake of 11,177 shares — an estimated $143K sold.

Kalos Management first reported a position in ARRY in Q4 2017 and held it in 1 quarter. The position peaked at $143K in Q4 2017. 235 funds tracked by Wall St. Rank hold ARRY as of Q1 2018.

Kalos Management reported no remaining Array Biopharma Inc position as of Q1 2018 after selling out during the quarter.
Kalos Management sold 11,177 Array Biopharma Inc shares in Q1 2018, an estimated $143K.
Kalos Management first reported a position in Array Biopharma Inc in Q4 2017 and held it in 1 quarter.
Kalos Management's Array Biopharma Inc position peaked at $143K in Q4 2017.
235 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2018.

Based on Kalos Management's 13F filing for Q1 2018, filed 14 May 2018.